ASCO Congress — a significat progress in the patient’s treatment with esophageal cancer 

Home - News

On the occasion of the ASCO congress (American society of Clinical Cancer), Pr. Eric Raymond has shown the positive results of a worldwide study of immunotherapy for oesophageal cancer. When tislelizumab, a new immunotherapy antibody, is given with the usual chemotherapy, it significantly improves the patient survival with a 34% lower risk of death.


Last news

Newsweek 2023

A warm thank you ! For 5 consecutive years, Saint-Joseph & Marie Lannelongue Hospitals have been ranked among the best hospitals over the world ! This year, due to

Read more »